Targeting Wild-Type and Mutationally Activated FGFR4 in Rhabdomyosarcoma with the Inhibitor Ponatinib (AP24534)
Samuel Q. Li(National Institutes of Health), Javed Khan(Kent State University), Laura Hurd, Jun S. Wei(Center for Cancer Research), Adam Cheuk(National Institutes of Health), Jack F. Shern(National Institutes of Health), Young Song(University of British Columbia), Hongling Liao(Broad Institute)
Cited by 100
Related Papers
Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks
|Nature Medicine|2001|2.7k
The genetic landscape of high-risk neuroblastoma
|Nature Genetics|2013|1.2k
Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors
|Cancer Discovery|2014|789
Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome
|Blood|2011|638
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
|Nature Genetics|2015|563